Edition:
United States

Profile: Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

187.27USD
3:43pm EDT
Change (% chg)

$0.95 (+0.51%)
Prev Close
$186.32
Open
$186.08
Day's High
$188.55
Day's Low
$185.42
Volume
1,579,577
Avg. Vol
2,991,524
52-wk High
$191.10
52-wk Low
$133.64

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Company Address

Amgen Inc

1 Amgen Center Dr
THOUSAND OAKS   CA   91320-1730
P: +1805.4471000
F: +1805.4471010

Company Web Links